Table 1 Baseline characteristics.

From: Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan

 

Gr 1 (Aflibercept) N = 41

Gr 2 (Ranibizumab) N = 43

p

Age

57.44 ± 10.87

59.65 ± 10.82

0.41

Sex (M: F)

18:17

23:14

0.48

HbA1c

7.53 ± 1.33

7.46 ± 1.75

0.85

Eye (OD: OS)

19:22

26:17

0.27

logMAR BCVA

0.60 ± 0.33

0.56 ± 0.33

0.59

CRT

426.02 ± 159.87

423.91 ± 111.28

0.94

VH

8/41

9/43

1.00

Pseudophakia

4/41

4/43

1.00

Previous PRP

11/41

15/43

0.48

Presence of ERM

11/41

19/43

0.12

DRIL

337.44 ± 296.97

311.56 ± 318.24

0.70

MAs

145.93 ± 46.77

137.19 ± 65.25

0.48

NV (disc size)

1.63 ± 1.80

1.28 ± 2.20

0.42

  1. Gr group, M male, F female, OD right eye, OS left eye, logMAR BCVA best-corrected visual acuity in the logarithm of the minimal angle of resolution, CRT central retinal thickness, VH vitreous hemorrhage, PRP panretinal photocoagulation, ERM epiretinal membrane, DRIL Disorganization of the retinal inner layers, MAs microaneurysms, NV retinal neovascularization.
Back to article page